Seroxo is a clinical-stage IVD company developing a proprietary point-of-care (POC) platform technology that enables rapid measurement of Immune Dysfunction, with applications in sepsis, cancer, and organ transplantation. With a clinical data package from 10x clinical trials in over 600 patients, Seroxo has demonstrated the superior performance and clinical benefit of its proprietary biomarker over competing biomarkers. Seroxo anticipates multiple licensing opportunities.

The Leukocyte ImmunoTest™ (LIT™), Seroxo’s finger-prick POC blood test assesses real-time neutrophil function through a patented 10-minute assay that has been shown to be superior to current biomarkers for a range of clinical applications, including sepsis, cancer, and organ perfusion/transplantation. Both clinical and home-use tests will be developed and launched in multiple territories worldwide.

Seroxo

Org chart

Teams

Offices

Seroxo

Org chart

Teams

Offices

Related companies